Who’s acquiring who? Immuno-oncology M&A activity in the pharmaceutical industry decreased by 8% in Q1 2023
Analysis of the key themes driving M&A activity reveals that immuno-oncology accounted for 12 pharmaceutical deals announced in Q1 2023,…
Analysis of the key themes driving M&A activity reveals that immuno-oncology accounted for 12 pharmaceutical deals announced in Q1 2023, worth a total value of $43.4bn. The $43bn acquisition of Seagen by Pfizer was the industry’s largest disclosed deal. A detailed classification of therapy and technologies, regulatory and market access details and pipeline analysis for immuno-oncology are included in GlobalData’s Immuno-Oncology – Thematic Research report. Buy the report here.
In value terms, immuno-oncology-related deal activity increased by 49% in Q1 2023 compared with the previous quarter’s total of $29.2bn and rose by 15491871% as compared to Q1 2022. Related deal volume decreased by 8% in Q1 2023 versus the previous quarter and was 100% higher than in Q1 2022.
The top-ranked financial advisors supporting these M&A deals in Q1 2023 were Centerview Partners; Greenhill; Guggenheim Partners with 1, 1, 1 deals respectively.
The top-ranked legal advisors supporting these M&A deals in Q1 2023 were White & Case; Cooley; Gibson, Dunn & Crutcher with 3, 2, 2 deals respectively.
For further understanding of GlobalData's Immuno-Oncology – Thematic Research buy the report here.
What's Your Reaction?
